Safety and Outcomes of Mechanical Thrombectomy in Acute Ischemic Stroke Attributable to Cardiological Diseases: A Scoping Review

Other authors

Institut Català de la Salut

[D’Anna L] Department of Stroke and Neuroscience Charing Cross Hospital, Imperial College London NHS Healthcare Trust London United Kingdom. Department of Brain Sciences Imperial College London London United Kingdom. [Abu‐Rumeileh S] Department of Neurology Martin‐Luther‐University Halle‐Wittenberg Halle (Saale) Germany. [Merlino G] Stroke Unit and Clinical Neurology Udine University Hospital Udine Italy. [Ornello R] Department of Biotechnological and Applied Clinical Sciences University of L’Aquila L’Aquila Italy. [Foschi M] Department of Biotechnological and Applied Clinical Sciences University of L’Aquila L’Aquila Italy. [Diana F] Servei de Neuroradiologia Intervencionista, Vall d’Hebron Hospital Universitari, Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2024-09-27T10:54:11Z

2024-09-27T10:54:11Z

2024-09-03



Abstract

Heart failure; Iischemic stroke; Mechanical thrombectomy


Insuficiència cardíaca; Ictus isquèmic; Trombectomia mecànica


Insuficiencia cardiaca; Ictus isquémico; Trombectomía mecánica


There is limited evidence on the outcomes and safety of mechanical thrombectomy (MT) among patients with acute ischemic stroke (AIS) in the context of cardiac diseases. Our study reviews MT in AIS within the context of cardiac diseases, aiming to identify existing and emerging needs and gaps. PubMed and Scopus were searched until December 31, 2023, using a combination of cardiological diseases and “mechanical thrombectomy” or “endovascular treatment” as keywords. Study design included case reports/series, observational studies, randomized clinical trials, and meta‐analyses/systematic reviews. We identified 943 articles, of which 130 were included in the review. Results were categorized according to the cardiac conditions. MT shows significant benefits in patients with atrial fibrillation (n=139) but lacks data for stroke occurring after percutaneous coronary intervention (n=2) or transcatheter aortic valve implantation (n=5). MT is beneficial in AIS attributable to infective endocarditis (n=34), although functional benefit may be limited. Controversy surrounds the functional outcomes and mortality of patients with AIS with heart failure undergoing MT (n=11). Despite technical challenges, MT appears feasible in aortic dissection cases (n=4), and in patients with left ventricular assist device or total artificial heart (n=10). Data on AIS attributable to congenital heart disease (n=4) primarily focus on pediatric cases requiring technical modifications. Treatment outcomes of MT in patients with cardiac tumors (n=8) vary because of clot consistency differences. After cardiac surgery stroke, MT may improve outcomes with early intervention (n=13). Available data outline the feasibility of MT in patients with AIS attributable to large‐vessel occlusion in the context of cardiac diseases.


Drs Abu‐Rumeileh and Barba received research support from the Medical Faculty of Martin‐Luther‐University Halle‐Wittenberg (Junior Clinician Scientist Programm No. JCS24/02).

Document Type

Article


Published version

Language

English

Publisher

Wiley

Related items

Journal of the American Heart Association;13(17)

https://doi.org/10.1161/JAHA.124.034783

Recommended citation

This citation was generated automatically.

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

This item appears in the following Collection(s)